# US 2025/0084176 A1 · Fc binding fragments comprising a cd137 antigen-binding site

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084176 A1
- Document ID: US20250084176A1
- Status: Published application
- Kind: A1
- Application number: 18/813,689
- Filed: 2024-08-23
- Published: 2025-03-13
- Earliest claimed: 2018-07-12
- Assignees: Invox Pharma Limited
- Applicants: invoX Pharma Limited
- Inventors: Matthew Lakins; Jose Munoz-Olaya; Sarka Pechouckova; Mihriban Tuna
- Web page: https://patentgrep.com/patent/US20250084176A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2887: {against CD20}
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/526: CH3 domain
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2318/10: Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to specific binding members that bind CD137. The specific binding members comprise a CD137 antigen-binding site located in a constant domain of the specific binding member and find application in the treatment of cancer and infectious diseases, for example.

## Claims

### Claim 1

A specific binding member that binds CD137 and comprises a CD137 antigen-binding site located in a CH3 domain of the specific binding member, the CD137 antigen-binding site comprising a first sequence located in the AB structural loop of the CH3 domain, wherein said first sequence comprises the sequence PPY (SEQ ID NO: 10).

### Claim 2 (depends on 1)

The specific binding member according to claim 1, wherein the specific binding member comprises an insertion in the AB structural loop.

### Claim 3 (depends on 2)

The specific binding member according to claim 2, wherein said insertion is 5 amino acids in length.

### Claim 4 (depends on 1)

The specific binding member according to claim 1, wherein the first sequence is the first sequence of specific binding member:
(i) FS22-172-003 set forth in SEQ ID NO: 138;
(ii) FS22-172-002 set forth in SEQ ID NO: 129;
(iii) FS22-172-004 set forth in SEQ ID NO: 147;
(iv) FS22-172-001 set forth in SEQ ID NO: 120;
(v) FS22-172-005 set forth in SEQ ID NO: 156;
(vi) FS22-172-006 set forth in SEQ ID NO: 110; or
(vii) FS22-172 set forth in SEQ ID NO: 110.

### Claim 5 (depends on 4)

The specific binding member according to claim 4, wherein the specific binding member further comprises a second sequence located in the EF structural loop of the CH3 domain, and wherein the second sequence is the second sequence of specific binding member FS22-172-003, FS22-172-002, FS22-172-004, FS22-172-001, FS22-172-005, FS22-172-006, or FS22-172 set forth in SEQ ID NO: 111.

### Claim 6 (depends on 1)

The specific binding member according to claim 1, wherein the specific binding member comprises the CH3 domain sequence of specific binding member:
(i) FS22-172-003 set forth in SEQ ID NO: 139;
(ii) FS22-172-002 set forth in SEQ ID NO: 130;
(iii) FS22-172-004 set forth in SEQ ID NO: 148;
(iv) FS22-172-001 set forth in SEQ ID NO: 121;
(v) FS22-172-005 set forth in SEQ ID NO: 157;
(vi) FS22-172-006 set forth in SEQ ID NO: 165; or
(vii) FS22-172 set forth in SEQ ID NO: 112.

### Claim 7 (depends on 1)

The specific binding member according to claim 1, wherein the specific binding member comprises the sequence of specific binding member FS22-172-003, FS22-172-002, FS22-172-004, FS22-172-001, FS22-172-005, FS22-172-006, or FS22-172 set forth in SEQ ID NO: 141, 132, 150, 123, 159, 167, and 114, respectively.

### Claim 8 (depends on 1)

The specific binding member according to claim 1, wherein the first sequence is the first sequence of specific binding member FS22-053-008, FS22-053-009, FS22-053-011, FS22-053-017, FS22-053-014, FS22-053-010, FS22-053-012, FS22-053-013, FS22-053-015, FS22-053-016, or FS22-053 set forth in SEQ ID NO: 19.

### Claim 9 (depends on 8)

The specific binding member according to claim 8, wherein the specific binding member further comprises a second sequence located in the EF structural loop of the CH3 domain, and wherein the second sequence is the second sequence of specific binding member:
(i) FS22-053-008 set forth in SEQ ID NO: 20;
(ii) FS22-053-009 set forth in SEQ ID NO: 29;
(iii) FS22-053-011 set forth in SEQ ID NO: 47;
(iv) FS22-053-017 set forth in SEQ ID NO: 101;
(v) FS22-053-014 set forth in SEQ ID NO: 74;
(vi) FS22-053-010 set forth in SEQ ID NO: 38;
(vii) FS22-053-012 set forth in SEQ ID NO: 56;
(viii) FS22-053-013 set forth in SEQ ID NO: 65;
(ix) FS22-053-015 set forth in SEQ ID NO: 83;
(x) FS22-053-016 set forth in SEQ ID NO: 92; or
(xi) FS22-053 set forth in SEQ ID NO: 174.

### Claim 10 (depends on 1)

The specific binding member according to claim 1, wherein the specific binding member comprises the CH3 domain sequence of specific binding member:
(i) FS22-053-008 set forth in SEQ ID NO: 21;
(ii) FS22-053-009 set forth in SEQ ID NO: 30;
(iii) FS22-053-011 set forth in SEQ ID NO: 48;
(iv) FS22-053-017 set forth in SEQ ID NO: 102;
(v) FS22-053-014 set forth in SEQ ID NO: 75;
(vi) FS22-053-010 set forth in SEQ ID NO: 39;
(vii) FS22-053-012 set forth in SEQ ID NO: 57;
(viii) FS22-053-013 set forth in SEQ ID NO: 66;
(ix) FS22-053-015 set forth in SEQ ID NO: 84;
(x) FS22-053-016 set forth in SEQ ID NO: 93; or
(xi) FS22-053 set forth in SEQ ID NO: 175.

### Claim 11 (depends on 1)

The specific binding member according to claim 1, wherein the specific binding member comprises the sequence of: specific binding member FS22-053-008, FS22-053-009, FS22-053-011, FS22-053-017, FS22-053-014, FS22-053-010, FS22-053-012, FS22-053-013, FS22-053-015, FS22-053-016, or FS22-053 set forth in SEQ ID NO: 23, 32, 50, 104, 77, 41, 59, 68, 86, 95, and 15, respectively.

### Claim 12 (depends on 1)

The specific binding member according to claim 1, wherein the specific binding member comprises the first sequence, first and second sequence, CH3 domain sequence, or sequence of specific binding member FS22-172-003 or FS22-053-008, preferably FS22-172-003.

### Claim 13 (depends on 1)

The specific binding member according to claim 1, wherein the specific binding member further comprises a CDR-based antigen-binding site.

### Claim 14 (depends on 13)

The specific binding member according to claim 13, wherein the specific binding member is an antibody molecule.

### Claim 15 (depends on 14)

The antibody molecule according to claim 14, wherein the CDR-based antigen-binding site binds a second antigen selected from the group consisting of: an immune cell antigen, a tumour antigen, and a pathogenic antigen.

### Claim 16 (depends on 1)

The specific binding member according to claim 1, wherein the specific binding member has been modified to reduce or abrogate binding of the specific binding member to one or more Fcγ receptors.

### Claim 17 (depends on 1)

A nucleic acid molecule encoding the specific binding member according to claim 1.

### Claim 18 (depends on 17)

A recombinant host cell comprising the nucleic acid according to claim 17.

### Claim 19 (depends on 1, 18)

A method of producing a specific binding member according to claim 1, comprising culturing the recombinant host cell of claim 18 under conditions for production of the specific binding member.

### Claim at position 20

-21. (canceled)

### Claim 22 (depends on 1)

The specific binding member according to claim 1, wherein the specific binding member is conjugated to a bioactive molecule.

### Claim 23 (depends on 14)

A pharmaceutical composition comprising the antibody molecule according to claim 14 and a pharmaceutically acceptable excipient.

### Claim 24 (depends on 14)

A method of treating a disease or disorder in an individual comprising administering to the individual a therapeutically effective amount of the antibody molecule according to claim 14.

### Claim 25 (depends on 24)

A method according to claim 24, wherein the treatment is the treatment of cancer or an infectious disease in an individual.
